Suppr超能文献

用于淋巴水肿研究的淋巴功能定量:储存清除率及血液中可溶性大分子的出现率

Quantification of lymphatic function for investigation of lymphedema: depot clearance and rate of appearance of soluble macromolecules in blood.

作者信息

Pain Simon J, Nicholas R Steven, Barber Robert W, Ballinger James R, Purushotham Arnie D, Mortimer Peter S, Peters A Michael

机构信息

Cambridge Breast Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.

出版信息

J Nucl Med. 2002 Mar;43(3):318-24.

Abstract

UNLABELLED

The object of this study was to develop a new technique for the quantitative measurement of lymphatic function. The rate of clearance of radiolabeled protein from a subcutaneous depot is supplemented by measurement of the appearance of the protein in venous blood. This initial study was performed on normal arms, with a view to subsequent clinical application such as in the investigation of women with breast cancer--related lymphedema (BCRL).

METHODS

Fourteen healthy volunteers (12 women, 2 men) and 8 women awaiting surgery for breast cancer were recruited for the study. Each received subcutaneous depot injection of protein solution in the second dorsal web space of each hand, labeled with (111)In on one side and with (99m)Tc on the other side. Human serum albumin (HSA) was the protein used in the first 8 subjects and human polyclonal immunoglobulin G (HIgG) was used thereafter. The activity at each depot was measured at regular intervals using a collimated sodium iodide scintillation detector, and the activity in venous blood sampled from both arms was measured in an automatic sample counter.

RESULTS

(99m)Tc-HSA cleared from the depot consistently faster than (111)In-HSA (P = 0.001). The proportions of radionuclide remaining bound to protein in venous blood were higher for (99m)Tc than for (111)In. HIgG displayed improved labeling stability for both nuclides, reflected in equal rates of clearance. Blood activity rose steadily after an early latent phase and for HIgG correlated strongly with the rate of clearance from the depot (P < 0.001). Marked variation between individuals was observed.

CONCLUSION

A dual-isotope technique relies on identical behavior of the 2 radiopharmaceuticals used. This study shows that this is the case with respect to HIgG but not HSA. (99m)Tc-HSA cleared faster than (111)In-HSA and yet displayed better in vivo labeling stability. We conclude that (111)In dissociates from HSA in the depot but then becomes locally bound. Using HIgG, a close correlation was observed between the rates of clearance from the depot and the appearance in venous blood. This finding suggests that HIgG would be a suitable marker for subsequent dual-isotope studies on women with BCRL.

摘要

未标注

本研究的目的是开发一种定量测量淋巴功能的新技术。通过测量静脉血中蛋白质的出现情况来补充皮下注射部位放射性标记蛋白质的清除率。这项初步研究在正常手臂上进行,以期后续应用于临床,如用于乳腺癌相关淋巴水肿(BCRL)女性的研究。

方法

招募了14名健康志愿者(12名女性,2名男性)和8名等待乳腺癌手术的女性参与研究。每个人在每只手的第二掌背间隙皮下注射蛋白质溶液,一侧用(111)铟标记,另一侧用(99m)锝标记。前8名受试者使用的蛋白质是人血清白蛋白(HSA),此后使用人多克隆免疫球蛋白G(HIgG)。使用准直碘化钠闪烁探测器定期测量每个注射部位的活性,并在自动样品计数器中测量从双臂采集的静脉血中的活性。

结果

(99m)锝 - HSA从注射部位清除的速度始终比(111)铟 - HSA快(P = 0.001)。静脉血中与蛋白质结合的放射性核素比例,(99m)锝比(111)铟更高。HIgG对两种核素均显示出更好的标记稳定性,表现为清除率相同。在早期潜伏期后,血液活性稳步上升,对于HIgG,其与从注射部位的清除率密切相关(P < 0.001)。观察到个体之间存在显著差异。

结论

双同位素技术依赖于所使用的两种放射性药物的相同行为。本研究表明,对于HIgG是这种情况,但对于HSA并非如此。(99m)锝 - HSA比(111)铟 - HSA清除得更快,但在体内显示出更好的标记稳定性。我们得出结论,(111)铟在注射部位从HSA解离,但随后局部结合。使用HIgG时,观察到从注射部位的清除率与在静脉血中的出现之间存在密切相关性。这一发现表明,HIgG将是后续对BCRL女性进行双同位素研究的合适标记物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验